A Phase 2, Open-Label, Multicenter, Randomized Study Evaluating NEOadjuvant immunotherapy Based Combinations in Patients with Resectable PANCreatic Ductal Adenocarcinoma (NEOiPANC)
A study of Neoadjuvant Immunotherapy Combinations in Patients with Pancreatic Ductal Adenocarcinoma (NEOiPANC)
Sponsor: Genentech
Enrolling: Male and Female Patients
IRB Number: AAAS1908
U.S. Govt. ID: NCT03979066
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine if treatment with atezolizumab and PEGylated Recombinant Human Hyaluronidase (PEGPH20), given before and after surgery, in addition to chemotherapy, is safe and if it can further increase the chance of cure. Approximately 40 patients will be asked to participate in this study, 20 randomized (chance of flipping a coin) to receive atezolizumab, and 20 randomized (chance of flipping a coin) to receive the combination of atezolizumab plus PEGPH20.
This study is closed
Investigator
Gulam Manji, MD, PhD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have a diagnosis of pancreatic adenocarcinoma? Yes No
Have you had any prior surgical, systemic, or radiotherapy for pancreatic adenocarcinoma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE